### PCT

# LLD INTELLECTUAL PROPERTY ORGANIZATION



TCT .		MIGHAI BUICAU
	(ED U	JNDER THE PATENT COOPERATION TREATY (PCT)  (11) International Publication Number: WO 96/10929
(51) International Patent Classification 6: A24D 3/14	A1	(11) International a concession of the concessio
A24D 3/14		(43) International Publication Date: 18 April 1996 (18.04.96)
(21) International Application Number: PCT/IBG (22) International Filing Date: 6 October 1995 (6) (30) Priority Data: 88544 7 October 1994 (07.10.94)  (71) Applicant (for all designated States except US): G.L [LU/LU]: 92, boulevard de la Pétrusse, L-2320 Lux (LU).  (72) Inventors; and (75) Inventors/Applicants (for US only): GARZIA, Ald Via Rimembranze 2, I-20075 Lodi-Milano (IT). Stefano [IT/IT]: Via Rimembranze 2, I-20075 Lo (IT).  (74) Agent: WEYLAND, J., J., Pierre: Marks & Cler Glesener, Boîte postale 1775, L-1017 Luxembour	06.10.9  [A.D. S. xembout of [IT/I] GARZ di-Milaterk, 6.	CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, US, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  Published  With international search report.
(54) Title: CIGARETTE FILTERS AND THE LIKE		
A filter for tobacco smoke comprises a free-radical together with an antioxidant to reduce the content of poly	inhibit ycyclic	for, particularly an O-alkylated derivative of 2,4-monofufurylidene sorbitol aromatic hydrocarbons in the smoke.

## FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

	·				
AT	Austria	GB	United Kingdom	MR	Mauritania
ΑÜ	Australia	GE	Georgia	MW	Malawi
88	Barbados	GN	Guinea	NE NE	
BE	Belgium	GR	Greece	NL NL	Niger
BF	Burkina Faso	HU	Hungary		Netherlands
BG	Bulgaria	IE	Ireland	.NO	Norway
BJ	Benin	ΙΤ	Italy	NZ	New Zealand
BR	Brazil	JP	Japan	PL	Poland
BY	Belarus	KE	•	PΤ	Portugal
CA	Canada	KG	Kenya	RO	Romania
CF	Central African Republic	KP	Kyrgystan	RU	Russian Federation
CG	Congo	K.F	Democratic People's Republic	SD	Sudan -
CH	Switzerland	***	of Korea	SE	Sweden
CI		KR	Republic of Korea	SI	Slovenia
CM	Côte d'Ivoire	KZ	Kazakhstan	SK	Slovakia
	Cameroon	LI	Liechtenstein	SN	Senegal
CN	China	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	ŢŢ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	ÜA	Ukraine
ES	Spain	MG	Madagascar	US	
FI	Finland	ML	Mali		United States of America
FR	France	MN	Mongolia	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

#### CIGARETTE FILTERS AND THE LIKE

The present invention is concerned with the treatment of filters for tobacco smoke, particularly cigarette filters, to limit the carcinogenic effect of the smoke passed by them to the consumer.

Tobacco smoke. particularly that from cigarettes, is well-known to contain various components which are either carcinogens or pro-carcinogens. One particular class of compounds falling within this category comprises the polycyclic aromatic hydrocarbons (PAH) which are converted by the cytochrome P450 enzyme system in the liver or the lung into oxygenated derivatives which have been shown to be carcinogenic. A considerable amount of literature now exists in this field, for example: Pryor, et al. Science 220:425-427; Pryor, et al. Cancer and Free-Radicals, in Antimutagenesis and Anticarcinogenesis Mechanisms: Ed. D Shankel, et al. Plenum Press, New York NY, pages 45-59; Janoff, et al. 1987 Am. Rev. Respir. Dis. 136:1058-1064 and many others. The effect of free-radicals in the smoke has been extensively discussed, for example by Church and Pryor Environ. Health. Perspect. 64:111-126 (1985).

20

10

15

GB-A-1044434 discloses the use of 2.4-monofurfurylidene sorbitol in cigarette filters to reduce the content of PAH in the smoke.

In situations where free-radicals are known to cause harm, for example in the skin, the use of free-radical inhibitors is well-known. For example, EP-B-O 345 362 discloses the use of a particular type of free-radical inhibitor in skin cosmetics. The inhibitor in question is chosen from a group of furfurylidene derivatives of sorbitol, in particular 2.4-monofurfurylidene sorbitol and the tetra-O-alkyl derivatives thereof. A method for preparing 2.4-monofurfurylidene sorbitol was disclosed in US-A-3.383.279 comprising gradual addition of furfurol to acidified sorbitol, thus forming the 2.4-O-furfurylidene derivative.

We have now investigated the effect of these sorbitol derivatives in other areas. Surprisingly, we have now found that the furfurylidene sorbitol derivatives of EP-B-O 345 362, in combinations with certain other components, can be used to impregnate tobacco smoke filters to achieve smoke which has a dramatically reduced content of PAH. The mechanism of this action is unknown and unexpected: on the model of previous uses of free-

radical inhibitors, it would be expected that the inhibitor must be present at the site of absorption by the body and not at a remote location. The compounds appear to remove mutagenic or carcinogenic compounds from the smoke, but other explanations are possible.

5

10

According to the present invention there is thus provided a filter for tobacco smoke comprising means forming a passageway for smoke, characterised in that on a surface of the passageway arranged to contact the smoke there is provided an O-alkylated derivative of 2.4-monofurfurylidene sorbitol together with an antioxidant. The O-alkylated derivative is desirably a  $C_{1-5}$ -alkyl derivative, e.g. the methyl derivative, and the tetra-O-alkyl derivative is preferred.

The filter according to the invention is particularly represented by a cigarette filter, which may have any conventional construction arranged to provide a very large surface area in contact with the smoke passing through, for example packed filaments, open-cell foams, etc.

The free-radical inhibitor may be incorporated in the filter at any effective level, but typically at 2.5-30 mg per filter, especially about 5-20 mg, particularly when tetra-O-methyl 2.4-monofurfurylidene sorbitol is used.

The filter also contains an antioxidant and the ratio by weight of the sorbitol derivative to the antioxidant is desirably from about 1.5:1 to 3:1. especially, about 2:1. Particularly preferred antioxidants comprise phenolic antioxidants such as *tert*-butyl-hydroxyanisole (BHA) or *tert*-butyl-hydroxytoluene (BHT).

It appears that there is synergy between the sorbitol derivative and the antioxidant, and both components are necessary for maximum activity.

The active components can be added to the cigarette filter by any convenient method. for example by dosing with a solution of the components and allowing the solvent to evaporate. Alternatively, the packing material for the filter can be pre-impregnated with the active component before the filter is constructed.

The following Example illustrates the invention further.

35

EXAMPLE - Measurement of benzo[ $\alpha$ ]pyrene and tar levels

In a series of tests, standard cigarettes were used - either Kentucky Reference 1R3F or commercial cigarettes containing no additives in the filter. The following additives were investigated:

2.4-monofurfurylidene sorbitol tetra-*O*-methyl ether (FT) *tert*-butyl-hydroxyanisole (BHA)

The results are summarised in the following table. The stated additive, dissolved in 40-60  $\mu$ l diethyl ether, was added in six to ten aliquots using a microsyringe to inject through the end of the filter. Control cigarettes were prepared using diethyl ether only. The cigarettes were stored in conditions of controlled humidity and temperature for twenty-four hours and were tested to check that there had been no change in the pressure drop across the filter.

The test methods were standar in the industry for the investigation of cigarette smoking and analysis of tobacco smoke. The cigarettes were "smoked" in a smoking machine conforming to the standard US Federal Trade Commission smoking protocol and the smoke was passed through a Cambridge filter, which was weighed before and after the smoking. The increase in weight of the filter is the total particulate matter (TPM). Nicotine was extracted from the filter by washing with alkaline methanol and estimated using gas chromatography using a nitrogen-phosphorus detection. The water content of the TPM was measured by extracting the filter with ethanol followed by gas chromatography with conductivity detection. Tar is calculated by deducting the nicotine and water contents from the TPM.

Benzo[ $\alpha$ ]pyrene (BaP) is taken as a representative carcinogen for tobacco smoke and was measured b. HPLC analysis (with fluorescence detection) of a cyclohexane extract ( e Cambridge filter.

20

25

. 4 -

TABLE

BHA (mg/cig) 0 0 10 30 1  Control 19.8	į		IADI		<del>,</del>			
Control 19.8   19.1   19.6   19.7   19.8   19.1   19.6   19.7   19.6   19.7   19.6   19.7   1			FT (mg/cig)	0	20/30	0	0	20
TPM (mg/cig)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Tar (mg/cig)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  FT (20 mg) + BHA (10 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20/30 mg)  FT (20/30 mg)  BHA (10 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)	ĺ		BHA (mg/cig)	0	0	10	30	10
TPM (mg/cig)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  FT (20/30 mg)  FT (20/30 mg)  BHA (10 mg)  FT (20/30 mg)  FT (20/30 mg)  FT (20 mg) + BHA (10 mg)  FT (20 mg) + BHA (10 mg)  FT (20 mg) + BHA (10 mg)  FT (20/30 mg)  FT (20/30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30 mg)  BHA (30 mg)  FT (20 mg) + BHA (30 mg)  BHA (30	5		Control	19.8				
(mg/cig)		70	FT (20/30 mg)		19.1			
BHA (30 mg)			BHA (10 mg)			19.6		
Control 15.1		J.	BHA (30 mg)				18.7	
Tar (mg/cig)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BHA (30 mg)  FT (20/30 mg)  BHA (10 mg)  Control  BHA (10 mg)  BHA (10 mg)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BAP (ng/cig)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (10 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BAP (ng/cig)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30 mg)  FT (20/30 mg)  BHA (30			FT (20 mg) + BHA (10 mg)					15.9
Tar	10		Control	15.1				
(mg/cig)	ļ	_	FT (20/30 mg)		14.4			
BHA (30 mg) FT (20 mg) + BHA (10 mg)  Nicotine (mg/cig) BHA (10 mg) BHA (10 mg) BHA (30 mg) BHA (30 mg) BHA (30 mg) BHA (30 mg) BHA (10 mg) BHA (30 mg			BHA (10 mg)			16.0		
FT (20 mg) + BHA (10 mg)   1.31   14   14   1.31   1.34   1.25	.	. 5 - 5,	BHA (30 mg)				14.9	
Nicotine (mg/cig)		<del></del>	FT (20 mg) + BHA (10 mg)					14.0
Nicotine (mg/cig)	15		Control	1.31				
(mg/cig)			FT (20/30 mg)		1.34			
BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BaP (ng/cig)  BHA (30 mg)  BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  BHA (30 mg)  FT (20 mg) + BHA (10 mg)  Control  BaP FT (20/30 mg)  BHA (10 mg)  BHA (30 mg)			BHA (10 mg)			1.24		
Control 14.3		, , ,	BHA (30 mg)				1.25	
Control 14.3   13.0   FT (20/30 mg)   13.0   13.7	-		FT (20 mg) + BHA (10 mg)					1.06
BaP (ng/cig) BHA (10 mg) 13.7  BHA (30 mg) 7.9  FT (20 mg) + BHA (10 mg) 6.6  Control 100 91 .  BaP FT (20/30 mg) 91 .  BHA (10 mg) 96 .  BHA (30 mg) 55	20	·	Control	14.3				
(ng/cig)			FT (20/30 mg)		13.0			
BHA (30 mg) 7.9  FT (20 mg) + BHA (10 mg) 6.6  Control 100  BaP FT (20/30 mg) 91  Control BHA (10 mg) 96  BHA (30 mg) 55			BHA (10 mg)			13.7		
25   Control 100		(5, 69)	BHA (30 mg)				7.9	
Control 100	. [_		FT (20 mg) + BHA (10 mg)					6.6
Control BHA (10 mg) 96  BHA (30 mg) 55	25		Control	100				
BHA (30 mg) 55		ВаР	FT (20/30 mg)		91			
BHA (30 mg) 55		Control	BHA (10 mg)			96		-
FT (20 mg) / PUA (10 mg)			BHA (30 mg)				55	
30			FT (20 mg) + BHA (10 mg)					46

As can be seen from the last column, for a 2:1 combination of FT and BHA, a highly significant reduction in BaP was noted.

35 Similar applications in other smoke filters can be envisaged, for example filter cartridges in tobacco pipes. An expert in the art will be

- 5 -

able to foresee several modifications and variations, which will be considered all included within the scope of the present specification.

BNSDOCID: <WO\_\_\_9610929A1\_1\_>

#### CLAIMS

10

20

25

- 1. A filter for tobacco smoke comprising means forming a passageway for smoke, characterised in that on a surface of the passageway arranged to contact the smoke there is provided an *O*-alkylated derivative of 2.4-monofurfurylidene sorbitol together with an antioxidant.
  - 2. A filter according to Claim 1, in which the antioxidant is a phenolic antioxidant.
- 3. A filter according to Claim 2. in which the antioxidant comprises tert-butyl-hydroxyanisole (BHA) or tert-butyl-hydroxytoluene (BHT).
- 4. A filter according to any of Claims 1 to 3, in which the *O*-alkylated derivative comprises 2.4-monofurfurylidene-1.3.5.6-tetra-*O*-methyl sorbitol.
  - 5. A filter according to any of Claims 1 to 4. in which the ratio by weight of the free-radical inhibitor to the antioxidant is from 1.5:1 to 3:1.
  - 6. A filter according to Claim 5. in which the ratio is about 2:1.
  - 7. A filter according to any of Claims 1 to 6 in the form of a cigarette filter.
  - 8. A filter according to Claim 7 containing 2.5 to 30 mg of the free-radical inhibitor.
- 9. A filter according to Claim 8 containing about 5 to 20 mg of the 30 free-radical inhibitor.

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 A24D3/14

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A24D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCU	MENTS	CONSIDERED	TO BE	RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	FR,A,1 533 175 (ISTITUTO CHEMIOTERAPICO ITALIANO) 19 July 1968 see the whole document	1-9
A	DATABASE WPI Week 9414 Derwent Publications Ltd., London, GB; AN 94-114240 & JP,A,06 062 824 (KYODO NYUGYO), 8 March 1994 see abstract	1
A	WO,A,94 00138 (VYREX CORPORATION) 6 January 1994 see page 3, line 9 - page 4, line 19 see page 8, line 1 - page 9, line 8; example 2	1

χ Patent family members are listed in annex.

•	Spean	CATEGORIES	οſ	aud	qocramenta	:
---	-------	------------	----	-----	------------	---

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document w: av throw doubts on priority claim(s) or which is cite. cabbish the publication date of another citation or our apecial reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- P\* document published prior to the international filing date but later than the priority date claimed
- "I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

4 January 1996

Date of mailing of the international search report

16.0L96

Name and mailing address of L . . . A

European Pater: Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Errawijk Tel. (+31-70) 3-2-2040, Tx, 31 651 epo nl, Fax: (+31-70) 3-6-3016 Authorized officer

Lepretre, F

Form PCT/ISA/210 (second sheet) (July 1992)

PC:/IB 95/00853

ategory *	On) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages    Relevant to claim No.		
·	GB,A,2 230 687 (PÉCSI DOHÁNYGYÁR) 31	Stant 10.	
	October 1990		
	•		
		·	

#### MILLUIATIONAL SEAKCH KEPUKI

on on patent tamily members

i/IB 95/00853

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
FR-A-1533175	22-11-68	BE-A- GB-A- US-A-	659231 1044434 3332427	25-07-67
WO-A-9400138	06-01-94	US-A- AU-B- CA-A- US-A-	5308874 4253793 2147348 5461080	03-05-94 24-01-94 06-01-94 24-10-95
GB-A-2230687	31-10-90	BE-A- DE-A- FR-A- JP-A- NL-A- SE-A- US-A-	1003263 3940901 2646325 2303475 9000005 8904109 5060672	11-02-92 31-10-90 02-11-90 17-12-90 16-11-90 29-10-90 29-10-91

THIS PAGE BLANK (USPTO)